Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 2/20 | 1.00 |
| ▸ | TEAD4 | Q15561 | 2/20 | 1.00 |
| ▸ | RNF114 | Q9Y508 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | TERT | O14746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30688878 | 0.91 | RNF114 (0.88) | YAP1TEAD4RNF114POLBMAPT | |
| SCHEMBL12857571 | 0.85 | YAP1 (0.74) | YAP1TEAD4POLB | |
| SCHEMBL12857635 | 0.83 | HTT (0.73) | YAP1TEAD4POLBKMT2AMAOB | |
| SCHEMBL1658926 | 0.81 | NT5E (0.82) | MAOB | |
| SCHEMBL2480894 | 0.80 | CA1 (0.75) | YAP1TEAD4KMT2AMAOBMAOA | |
| SCHEMBL23518678 | 0.80 | RNF114 (0.91) | YAP1TEAD4RNF114KMT2AMAOB | |
| SCHEMBL27465865 | 0.79 | RNF114 (0.88) | YAP1TEAD4RNF114MAPTKMT2A | |
| SCHEMBL28185892 | 0.78 | MAOB (0.78) | YAP1TEAD4KMT2AMAOBMAOA | |
| SCHEMBL21392923 | 0.78 | YAP1 (0.63) | YAP1TEAD4RNF114KMT2AMAOB | |
| SCHEMBL16210967 | 0.78 | YAP1 (0.64) | YAP1TEAD4KMT2AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | YAP1 1622/4885TEAD4 1748/4885RNF114 769/4885 |
| US-11666661-B2 | Methods and compounds for targeted autophagy | ATG7, BECN1, SQSTM1 | YAP1 1622/4885TEAD4 1748/4885RNF114 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.